ICD 2025: New data demonstrate Nemluvio’s (nemolizumab) favorable safety profile and sustained and c
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1
Results build on data from OLYMPIA
来源：
作者：
